2-氰基-N-(3-羟丙基)-乙酰胺 | 116315-12-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氰基-N-(3-羟丙基)-乙酰胺
• 英文名称: 2-cyano-N-(3-hydroxypropyl)acetamide
• 英文别名: N-(3-hydroxypropyl)cyanoacetamide
• CAS: 116315-12-9
• 化学式: C₆H₁₀N₂O₂
• mdl: MFCD09906993
• 分子量: 142.158
• InChiKey: PTDWEZSSIVHKSU-UHFFFAOYSA-N

物化性质

• 沸点：
  430.2±30.0 °C(Predicted)
• 密度：
  1.142±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  73.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氰基-N-(3-羟丙基)-乙酰胺 在 二月桂酸二丁基锡 作用下， 以 乙醇 、 氯仿 为溶剂， 60.0~80.0 ℃ 、1.03 MPa 条件下， 反应 5.0h， 生成 bis(3-(4-oxopyrimido[4,5-b][1,8]naphthyridin-3(4H)-yl)propyl)hexane-1,6-diyldicarbamate
  参考文献：
  名称：

  功能齐全的AAA–DDD三重氢键基序†

  摘要：

  在这里，我们提出了一种新的，易于官能化的AAA-DDD氢键阵列。一种新的AAA单体单元（3a–b）是通过两步合成过程从2-氨基烟碱醛开始通过微波辐射获得的（总收率为52–66％）。1 H NMR和荧光光谱证实了络合事件，计算的缔合常数为1.57×10 7 M -1。同样，通过在交联的超分子交替共聚物中的粘度测量证明了该三氢键基序在超分子聚合中的有用性。

  DOI：

  10.1039/c8ob00479j
• 作为产物：
  描述：

  氰乙酸乙酯 、 3-氨基-1-丙醇 以 乙醇 为溶剂， 反应 2.0h， 以100%的产率得到2-氰基-N-(3-羟丙基)-乙酰胺
  参考文献：
  名称：

  Polymorphic study and anti-inflammatory activity of a 3-cyano-2-pyridone based flexible model

  摘要：

  本研究对2-{3-[3-氰基-6-甲基-2-氧代-4-苯基吡啶-1(2<斜体>H)-基]丙氧基}-4-甲基-6-苯基烟酰亚胺(2)进行了多态解释和生物评估。

  DOI：

  10.1039/c5nj03683f

文献信息

• Pharmacologically active compounds, methods for the preparation thereof
  申请人：Orion-yhtyma Oy

  公开号：US04963590A1

  公开（公告）日：1990-10-16

  Pharmacologically active catechol derivatives of formula I ##STR1## wherein R.sub.1 and R.sub.2 independently comprise hydrogen, alkyl, acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcabamoyl or taken together form a lower alkylidene or cycloalkylidene, X comprises an electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, aldehyde, caboxyl or trifluoromethyl and R.sub.3 comprises hydrogen, halogen, hydroxy alkyl, amino, nitro, cyano, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkyl carbonyl, aralkylidene carbonyl or carboxyl or a group selected from ##STR2## wherein R.sub.4 comprises hydrogen, alkyl, cyano, carboxyl or acyl and R.sub.5 comprises hydrogen, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, optionally substituted aroyl or heteroaroyl, hydroxyalkyl or carboxyalkyl or R.sub.4 and R.sub.5 together form a five to seven membered substituted cycloalkanone ring; --(CO).sub.n (CH.sub.2).sub.m --COR wherein n is 0-1 and m is 0-7 and R comprises hydroxy, alkyl, carboxyalkyl, optionally substituted alkene, alkoxy or optionally substituted amino; ##STR3## wherein R.sub.8 and R.sub.9 independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, or together form an optionally substituted piperidyl group; --NH--CO--R.sub.10 wherein R.sub.10 comprises a substituted alkyl group.

  公式I的药理活性儿茶酚衍生物，其中R.sub.1和R.sub.2独立地包括氢、烷基、酰基、可选择地取代的芳酰基、较低的烷基磺酰基或烷基氨基甲酰基，或者一起形成较低的烷基亚甲基或环烷基亚甲基，X包括电负取代基，如卤素、硝基、氰基、较低的烷基磺酰基、磺胺基、醛基、羧基或三氟甲基，R.sub.3包括氢、卤素、羟基烷基、氨基、硝基、氰基、三
• PROCESS FOR PREPARING SUBSTITUTED PYRIDONE COMPOUNDS
  申请人：Xerox Corporation

  公开号：US20040006234A1

  公开（公告）日：2004-01-08

  Disclosed is a process for preparing substituted pyridone compounds which comprises (a) admixing in the absence of a solvent (1) an amine of the formula R 1 —NH 2 wherein R 1 is an alkyl group, an aryl group, an arylalkyl group, or an alkylaryl group, and (2) a first ester of the formula 1 wherein R 2 is an electron withdrawing group and R 3 is an alkyl group; (b) heating the mixture containing the amine and the first ester to form an intermediate compound of the formula 2 (c) admixing the intermediate compound with (1) a base and (2) a second ester of the formula 3 wherein R 4 is an alkyl group, an aryl group, an arylalkyl group, or an alkylaryl group and R 5 is an alkyl group, said second ester being present in a molar excess relative to the intermediate compound, said base being present in a molar excess relative to the intermediate compound, and (d) heating the mixture containing the intermediate compound, the second ester, and the base to form a pyridone compound of the formula 4 or a salt thereof. Also disclosed is a process for preparing diazopyridone colorants which comprises preparing a pyridone compound by the above process and reacting the pyridone compound with a diazonium salt to form a diazopyridone compound.

  揭示了一种制备取代吡啶酮化合物的过程，包括(a)在无溶剂的情况下混合（1）具有R1—NH2式的胺，其中R1是烷基、芳基、芳基烷基或烷基芳基，以及（2）具有R2为电子吸引基团和R3为烷基的第一酯的混合；（b）加热含有胺和第一酯的混合物以形成具有式2的中间化合物；（c）将中间化合物与（1）碱和（2）具有R4为烷基、芳基、芳基烷基或烷基芳基以及R5为烷基的第二酯混合，其中所述第二酯相对于中间化合物存在摩尔过量，所述碱相对于中间化合物存在摩尔过量，并且（d）加热含有中间化合物、第二酯和碱的混合物以形成具有式4的吡啶酮化合物或其盐。还揭示了一种制备重氮吡啶酮染料的过程，包括通过上述过程制备吡啶酮化合物，并将吡啶酮化合物与重氮盐反应以形成重氮吡啶酮化合物。
• Pharmacologically active catechol derivatives
  申请人：Orion-yhtyma Oy

  公开号：US05446194A1

  公开（公告）日：1995-08-29

  A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.

  根据公式1，化合物的结构为：##STR1## 其中，R.sub.1和R.sub.2独立地表示氢、被1到4个碳原子的烷基取代的氨基甲酰基、2到5个碳原子的烷基羰基或苯基羰基，X表示卤素、硝基或氰基，而R.sub.3表示##STR2## 其中，R.sub.4表示氰基或2到5个碳原子的烷基羰基，R.sub.5表示未取代或被1到8个碳原子的烷基取代的氨基甲酰基，或被1到8个碳原子的羟基烷基取代的氨基甲酰基，或药学上可接受的酯和盐，以及其药学上可接受的载体。此外，还包括将该化合物作为COMT抑制剂的药物组合物。
• Method of treating Parkinson's Disease using pentanedione derivatives
  申请人：Orion-yhtyma Oy

  公开号：US05112861A1

  公开（公告）日：1992-05-12

  The invention concerns a method for the treatment of Parkinson's Disease. The method comprises administering a catechol-O-methyl-transferase inhibiting amount of a compound having the formula I ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, alkylcarbamoyl of 2 to 5 carbon atoms or alkylcarbonyl of 2 to 5 carbon atoms, X represents nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents cyano; alkylcarbonyl of 2 to 5 carbon atoms; or carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, or hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable salts or esters thereof; and a sufficient amount of levodopa to treat Parkinson's Disease. A peripheral decarboxylase inhibitor such as carbidopa or benzerazide is also preferably administered.

  本发明涉及一种治疗帕金森病的方法。该方法包括向患者施用一种具有以下式子I的化合物，其中R1和R2独立地表示氢、2至5个碳原子的烷基氨基酰基或2至5个碳原子的烷基羰基，X表示硝基或氰基，R3表示下列式子：其中R4表示氰基或2至5个碳原子的烷基羰基，R5表示氰基、2至5个碳原子的烷基羰基、未取代或取代了1至8个碳原子的烷基、1至8个碳原子的羟基烷基的氨基甲酰基或其药学上可接受的盐或酯；以及足够的左旋多巴治疗帕金森病。此外，最好还要施用周围脱羧酶抑制剂，如卡比多巴或苯扎酰胺。
• Synthesis and structure–activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo–keto reductase (AKR) 1B10
  作者：Satoshi Endo、Dawei Hu、Miho Suyama、Toshiyuki Matsunaga、Kenji Sugimoto、Yuji Matsuya、Ossama El-Kabbani、Kazuo Kuwata、Akira Hara、Yukio Kitade、Naoki Toyooka

  DOI：10.1016/j.bmc.2013.08.059

  日期：2013.11

  Inhibitors of a human member (AKR1B10) of the aldo-keto reductase superfamily are regarded as promising therapeutics for the treatment of cancer. Recently, we have discovered (Z)-2(4-methoxyphenylimino)-7-hydroxy-N-(pyridin-2-yl)-2H-chromene-3-carboxamide (1) as the potent competitive inhibitor using the virtual screening approach, and proposed its 4-methoxy group on the 2-phenylimino moiety as an essential structural prerequisite for the inhibition. In this study, 18 derivatives of 1 were synthesized and their inhibitory potency against AKR1B10 evaluated. Among them, 7-hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic acid benzylamide (5n) was the most potent inhibitor showing a K-i value of 1.3 nM. The structure-activity relationship of the derivatives indicated that the 7-hydroxyl group on the chromene ring, but not the 4-methoxy group, was absolutely required for inhibitory activity, The molecular docking of 5n in AKR1B10 and site-directed mutagenesis of the enzyme residues suggested that the hydrogen-bond interactions between the 7-hydroxyl group of 5n and the catalytic residues (Tyr49 and His111) of the enzyme, together with a pi-stacking interaction of the benzylamide moiety of 5n with Trp220, are important for the potent inhibition. (C) 2013 Elsevier Ltd. All rights reserved.